Among other things, motility of at least one individual microorganism or a change in motility of at least one individual microorganism or both is or are characterized. The characterized motility or change in motility is used to detect the presence or count of the at least one individual microorganism, or determine the identity of a species or strain of the at least one individual microorganism, or determine a susceptibility of the at least one individual microorganism to one or more antibiotics or other antimicrobials.

Embodiments of the present disclosure present novel systems, devices and methods for an automated biological sample analysis using mass-spectrometry. The time from sample introduction to the reporting of data, in some embodiments, takes a relatively short amount of time (e.g., several minutes). In some embodiments, a biological sample to be analyzed is a blood sample. For many applications, only a single drop of blood may be sufficient. Through the use of a mixture of standards with unique molecular mass, a quantitative analysis of the target analyte can be performed in a single MS run (for example), eliminating the need to create and analyze standard curves. One advantage of such embodiments may be that the system, devices, and methods can eliminate the need for batch creation since the requirement to amortize the time and effort of creating and analyzing standard curves can be eliminated.

This invention provides:an aptamer-based electrochemical sensor, wherein said aptamer is covalently bonded to or chemisorbed on an electrode, said aptamer forming a complex with a target molecule and is encapsulated by a gelatin B matrix;a method of manufacturing said aptamer-based electrochemical sensor;the use of the aptamer-based electrochemical sensor for the electrochemical determination of a concentration of a target molecule; anda composite electrode combining a polymeric material and electrically conducting particles for selective analyte detection, wherein said electrode is coated with gelatin type B.

Among other things, motility of at least one individual microorganism or a change in motility of at least one individual microorganism or both is or are characterized. The characterized motility or change in motility is used to detect the presence or count of the at least one individual microorganism, or determine the identity of a species or strain of the at least one individual microorganism, or determine a susceptibility of the at least one individual microorganism to one or more antibiotics or other antimicrobials.

Embodiments described herein include detecting an analyte in a low pH sample. Some embodiments include detection of multiple analytes in a sample utilizing a plurality of analyte binders and a control zone containing multiple control zone capture agents. In some embodiments, the multiple control zone capture agents capture a plurality of binders within one control zone.

The invention relates to haptens, immunogens and secondary immunoreactive agents, to the use thereof for producing wide-spectrum antibodies against quinolone-type antibiotics, to the application thereof to immunochemical analysis techniques, and to a kit enabling the detection of said antibiotics in biological samples from food products of animal origin.

A multilayer Paper Analytical Device (PAD) and method for detection of a low quality pharmaceutical or dietary supplement product. The multilayer PAD includes one or more assay regions, one or more reagent vessels in registry with the assay region(s), and a non-chemically interfering binder agent disposed between the assay regions and vessels, so that rupture of the vessels enables the reagents to wet the assaying regions and contact a sample of a suspected low quality pharmaceutical product or dietary supplement for testing thereof. A kit is also provided for detection of a low quality pharmaceutical or dietary supplement product, the kit including a multilayer PAD and instructions for using the kit.

Embodiments of the present disclosure present novel systems, devices and methods for an automated biological sample analysis using mass-spectrometry. The time from sample introduction to the reporting of data, in some embodiments, takes a relatively short amount of time (e.g., several minutes). In some embodiments, a biological sample to be analyzed is a blood sample. For many applications, only a single drop of blood may be sufficient. Through the use of a mixture of standards with unique molecular mass, a quantitative analysis of the target analyte can be performed in a single MS run (for example), eliminating the need to create and analyze standard curves. One advantage of such embodiments may be that the system, devices, and methods can eliminate the need for batch creation since the requirement to amortize the time and effort of creating and analyzing standard curves can be eliminated.

The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.

Disclosed is a method and apparatus for determining a concentration of a glycopeptide antibiotic containing a phenol moiety such as Vancomycin in a complex sample matrix by extracting the glycopeptide antibiotic from a metered portion of the complex sample matrix by exposing said metered portion to an extraction material having an affinity with the glycopeptide antibiotic; and exposing the extraction material to a metered portion of an eluent for releasing the glycopeptide antibiotic from the extraction material; and by determining a concentration of the glycopeptide antibiotic by adding a Gibbs reagent (2,6 dichloroquinone-4-chloroimide) to the metered portion of the complex sample matrix or the eluent; activating the Gibbs reagent and, after the reaction between the activated Gibbs reagent and the antibiotic has stabilized; detecting the reaction product of the activated Gibbs reagent and the antibiotic in said eluent; and determining the concentration of the antibiotic in the complex sample matrix from the detected reaction product. A method of designing a personalized drug administration regime using the thus obtained concentration is also disclosed.